Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 27, 2026

Amesite Announces Up To $6 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

View original at globenewswire.com
Amesite Announces Up To $6 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules DETROIT, April 27, 2026 (GLOBE NEWSWIRE) -- Amesite Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Amesite is an AI-driven company with an immediate aim to transform the $330 billion home and healthcare segments

    60% confidence
  • The Company intends to use the net proceeds from the offerings for general corporate purposes, including working capital

    60% confidence
  • NurseMagic™ is built on proprietary AI trained on industry-specific data, meets HIPAA regulations while improving accuracy and efficiency

    60% confidence
  • NurseMagic™ is used by over 100 professions to improve care, enhance operational efficiency and improve financial performance

    60% confidence
  • The aggregate gross proceeds from the offerings are expected to be approximately $2 million, before deducting placement agent fees and other offering expenses

    60% confidence
  • NurseMagic™ streamlines documentation for nurses and caregivers, reducing the time required from 20 minutes to just 20 seconds

    60% confidence
  • The NurseMagic™ platform serves B2B and B2C users across 50 states and 21 countries, offering translations to over 50 languages

    60% confidence
  • The potential additional gross proceeds from the warrants, if fully exercised on a cash basis, will be approximately $4 million — no assurance can be given that any warrants will be exercised

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com